Brixadi (buprenorphine) is a prescription drug that’s used to treat opioid use disorder (OUD). Brixadi comes as a liquid solution in a prefilled syringe. You’ll receive Brixadi as an injection under ...

Credit: Braeburn. Brixadi (weekly) and Brixadi (monthly) are different formulations. Brixadi ® (buprenorphine) extended-release subcutaneous injection is now available for the treatment of moderate to ...

LUND, Sweden, June 26, 2021 /PRNewswire/ — Camurus (NASDAQ STO: CAMX) announced today that the New Drug Application (NDA) by Camurus’ US licensee Braeburn for BrixadiTM (buprenorphine) ...

In this part of his Pharmaceutical Executive video interview, Joshua M. Cohen, MD, MPH, FAHS, Chief Medical Officer, Braeburn discusses data from the Phase III trial recently published in JAMA and how ...

Brixadi will be supplied as weekly (8mg, 16mg, 24mg, 32mg) and monthly (64mg, 96mg, 128mg) injections. The tentative approval means the FDA concluded Brixadi met all the required safety, efficacy, and ...

Brixadi is the first treatment for opioid use disorder in the US with both weekly and monthly dosing Three million people in the US diagnosed with opioid use disorder OUD is a complex and potentially ...

Please provide your email address to receive an email when new articles are posted on . The FDA tentatively approved certain Brixadi injections for treatment of moderate to severe opioid use disorder, ...

LUND, Sweden, June 1, 2020 /PRNewswire/ -- Camurus AB (NASDAQ: CAMX) (STO: CAMX) today announces that the company's US partner Braeburn has submitted a request for final approval of Brixadi™ ...